About Gilboa Therapeutics

Gilboa Therapeutics is developing SolidT technology, a proprietary engineered T cell therapy that utilizes tumor-specific antibodies to target and eliminate solid tumor cells. This approach addresses the limited efficacy of current immunotherapies in treating solid tumors, aiming to improve patient response rates and outcomes.

```xml <problem> Current cancer immunotherapies, such as CAR-T cell therapy, have shown limited efficacy in treating solid tumors due to the inaccessibility of these tumors and potential for dangerous side effects. This results in many patients not responding to available treatments, highlighting the urgent need for next-generation T cell therapies capable of eradicating solid tumors with improved safety. </problem> <solution> Gilboa Therapeutics is developing SolidT, an engineered T cell therapy designed to target and eliminate solid tumor cells with enhanced precision and safety. SolidT cells are genetically modified to express a high-affinity antibody receptor, enabling them to identify and target tumor cells labeled by tumor-specific antibodies. This approach delivers a potent and specific attack, eradicating tumor cells while leaving healthy tissue unharmed, as demonstrated in preclinical mouse models. The SolidT platform aims to improve patient response rates and outcomes across a range of solid and hematological tumors by overcoming the limitations of conventional CAR-T therapies. </solution> <features> - T cells genetically engineered to express a modified, high-affinity antibody receptor - Targets tumor cells via tumor-specific antibodies, enhancing specificity - Designed for potent and precise eradication of tumor cells, sparing healthy tissue - Demonstrated complete tumor remission in preclinical mouse models - Potential for improved safety profile compared to other cell therapy approaches - Applicable to a range of solid and hematological tumors </features> <target_audience> The primary target audience includes cancer patients with solid tumors who are not responding to current immunotherapies, as well as clinicians and researchers seeking more effective and safer cell therapy options. </target_audience> ```

What does Gilboa Therapeutics do?

Where is Gilboa Therapeutics located?

Gilboa Therapeutics is based in Ho, Israel.

When was Gilboa Therapeutics founded?

Gilboa Therapeutics was founded in 2021.

Location

Ho, Israel

Founded

2021

Employees

4 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Gilboa Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

gilboa.bio 700+

Crunchbase

Founded 2021 – Ho, Israel

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Current cancer immunotherapies, such as CAR-T cell therapy, have shown limited efficacy in treating solid tumors due to the inaccessibility of these tumors and potential for dangerous side effects. This results in many patients not responding to available treatments, highlighting the urgent need for next-generation T cell therapies capable of eradicating solid tumors with improved safety.

Solution

Gilboa Therapeutics is developing SolidT, an engineered T cell therapy designed to target and eliminate solid tumor cells with enhanced precision and safety. SolidT cells are genetically modified to express a high-affinity antibody receptor, enabling them to identify and target tumor cells labeled by tumor-specific antibodies. This approach delivers a potent and specific attack, eradicating tumor cells while leaving healthy tissue unharmed, as demonstrated in preclinical mouse models. The SolidT platform aims to improve patient response rates and outcomes across a range of solid and hematological tumors by overcoming the limitations of conventional CAR-T therapies.

Features

T cells genetically engineered to express a modified, high-affinity antibody receptor

Targets tumor cells via tumor-specific antibodies, enhancing specificity

Designed for potent and precise eradication of tumor cells, sparing healthy tissue

Demonstrated complete tumor remission in preclinical mouse models

Potential for improved safety profile compared to other cell therapy approaches

Applicable to a range of solid and hematological tumors

Target Audience

The primary target audience includes cancer patients with solid tumors who are not responding to current immunotherapies, as well as clinicians and researchers seeking more effective and safer cell therapy options.